Overall, 98/1627 (6.0%) of EGFR mutations and 54/2387 (2.3%) of TP53 mutations in human lung cancers are doublets, a much higher frequency than that observed in the lacI gene in Big Blue mice (8-fold and 3-fold, respectively) (Table 2). This evidence concerns the gene TFPI and lung cancer.